Latest Healthcare It News

Oceania Healthcare Limited reported a robust 1HY26 performance, marked by increased sales volumes, improved care profitability, and disciplined capital management. The company’s strategic focus on sales, operational excellence, and debt reduction sets a solid foundation for sustainable growth.

Oceania Healthcare reports a robust interim result for the six months to September 2025, with significant earnings growth, improved sales, and a reduction in debt gearing. The company’s strategic focus on cost control, capital management, and sustainable care delivery underpins its positive outlook despite housing market headwinds.

Oceania Healthcare has posted a strong half-year turnaround with improved sales, cost savings, and reduced gearing, setting the stage for renewed growth and operational strength.

Oceania Healthcare reported a slight dip in revenue but impressive gains in profitability for the first half of 2025, highlighting operational resilience amid a challenging environment.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a brief delay as FIRB extends its approval deadline, prompting a reschedule of the critical court hearing to November 23.

Monash IVF Group reported a 6.7% revenue increase to $271.9 million for FY25, alongside an 8.1% decline in underlying NPAT, aligning with prior guidance. The company outlined a cautious FY26 outlook focused on innovation, doctor retention, and cost management.

Monash IVF Group reported solid FY25 revenue and EBITDA growth despite sector softness and clinical incidents, while announcing a leadership transition and dividend pause.

SKS Technologies reported a remarkable doubling of profit in FY25, driven by strong organic growth and a strategic acquisition that positions it for rapid expansion in Australia's largest data centre market.

Emyria Limited is fast-tracking its national rollout of Empax mental health clinics, backed by a strong $8 million institutional placement and new dual-payer funding pathways.

HITIQ Limited has launched its PROTEQT™ concussion management system in North America, securing exclusive Canadian distribution rights and initiating a dual-channel market strategy targeting hockey’s vast ecosystem.

Acorn Capital Investment Fund Limited (ACQ) reported a strong FY25 performance with a 15.1% net return and declared 5.5 cents per share in dividends, reinforcing its position in the Australian microcap sector.

Amplia Therapeutics has secured positive feedback from the US FDA on its Phase 2b/3 trial design for narmafotinib in pancreatic cancer, paving the way for a late 2026 trial start.